U.S. ATP Assays Market Size, Share, Trends, Industry Analysis Report By Type, By Application, By End Use

Description

List of Tables

The U.S. ATP Assays market size is expected to reach USD 1.54 billion by 2034, according to a new study by Polaris Market Research. The report "U.S. ATP Assays Market Share, Size, Trends, Industry Analysis Report By Type [Luminometric ATP Assays, Enzymatic ATP Assays, Bioluminescence Resonance Energy Transfer (BRET) ATP Assays, Cell-based ATP Assays, Others], By Application, By End Use; Market Forecast, 2025-2034" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Adenosine triphosphate (ATP) assays are biochemical tests used to measure ATP levels in biological samples. ATP, the primary energy carrier of cells, is present in all living organisms, making its detection a reliable marker for cell health and proliferation. ATP assays are widely used in microbiology for testing microbial contamination, in cell biology to assess cytotoxicity and drug efficacy, and in environmental monitoring to evaluate the cleanliness of water or surfaces. Industries such as pharmaceuticals, food safety, and healthcare rely on ATP assays for quality control, sterility testing, and hygiene monitoring. The speed, accuracy, and versatility of ATP assays make them essential in research and industrial applications where real-time assessment of cellular activity is crucial.

In the U.S., ATP assays are widely used across healthcare, biotechnology, and industrial sectors, adhering to stringent regulatory standards established by agencies such as the FDA and EPA. The U.S. market for ATP assays is driven by advancements in bioluminescence technology and increasing demand for rapid microbial detection in food safety, pharmaceuticals, and clinical diagnostics. Companies such as Promega, Thermo Fisher Scientific, and Merck dominate the market, offering high-throughput and portable ATP detection systems. The U.S. emphasizes ATP testing in hospital hygiene to prevent infections, in water treatment facilities for microbial monitoring, and in drug development for cytotoxicity screening. Additionally, the Environmental Protection Agency (EPA) employs ATP assays to assess drinking water quality. The growing focus on automation and miniaturization in diagnostic tools further propels the adoption of ATP assays in the U.S.

U.S. ATP Assays Market Report Highlights

In terms of type, the luminometric ATP assays segment held the largest U.S. ATP assays market share in 2024 due to its high sensitivity, rapid results, and widespread adoption in research and diagnostic applications.

The cell-based ATP assays segment is projected to grow at a robust pace in the coming years, owing to the rising focus on cell viability and cytotoxicity studies in drug development and cancer research.

Based on application, the drug discovery and development segment dominated the revenue share in 2024 due to increasing demand for high-throughput screening and the growing emphasis on precision medicine.

In terms of end use, the pharmaceutical and biotechnology companies segment accounted for a major market share in 2024 due to their extensive use of adenosine triphosphate (ATP) assays in drug discovery, preclinical development, and quality control processes.

A few key players in the U.S. ATP assays market include Abcam plc; Becton, Dickinson and Company (BD); Biomerieux SA; Merck KGaA; Lonza Group Ltd.; PerkinElmer Inc.; Promega Corporation; Quest Diagnostics Incorporated; and Thermo Fisher Scientific.

Polaris Market Research has segmented the U.S. ATP assays market report on the basis of type, application, and end use:

By Type Outlook (Revenue, USD Billion, 2020-2034)

Luminometric ATP Assays

Enzymatic ATP Assays

Bioluminescence Resonance Energy Transfer (BRET) ATP Assays

Cell-based ATP Assays

Others

By Application Mode Outlook (Revenue, USD Billion, 2020-2034)

Drug Discovery and Development

Clinical Diagnostics

Environmental Testing

Food Safety and Quality Testing

Others

By End Use Outlook (Revenue, USD Billion, 2020-2034)

Pharmaceutical and Biotechnology Companies

Academic and Research Institutes

Hospital and Diagnostics Laboratories

Product Code: PM6131

1. Introduction

1.1. Report Description
- 1.1.1. Objectives of the Study
- 1.1.2. Market Scope
- 1.1.3. Assumptions
1.2. Stakeholders

2. Executive Summary

2.1. Market Highlights

3. Research Methodology

3.1. Overview
- 3.1.1. Data Mining
3.2. Data Source
- 3.2.1. Primary Source
- 3.2.2. Secondary Source

4. U.S. ATP Assays Market Insights

4.1. ATP Assays Market - Market Snapshot
4.2. ATP Assays Market Dynamics
- 4.2.1. Drivers and Opportunities
  - 4.2.1.1. Expanding application in Pharmaceutical and Biotechnology Research
  - 4.2.1.2. Rising Burden of Chronic Diseases
- 4.2.2. Restraints and Challenges
  - 4.2.2.1. Lack of specificity for microbial vs. non-microbial ATP
4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers (Moderate)
- 4.3.2. Threats of New Entrants: (Low)
- 4.3.3. Bargaining Power of Buyers (Moderate)
- 4.3.4. Threat of Substitute (Moderate)
- 4.3.5. Rivalry among existing firms (High)
4.4. PESTEL Analysis
4.5. ATP Assays Market End Use Trends
4.6. Value Chain Analysis

5. U.S. ATP Assays Market, by Type

5.1. Key Findings
5.2. Introduction
- 5.2.1. U.S. ATP Assays Market, by Type, 2020-2034 (USD Billion)
5.3. Luminometric ATP Assays
- 5.3.1. U.S. ATP Assays Market, by Luminometric ATP Assays, by Region, 2020-2034 (USD Billion)
5.4. Enzymatic ATP Assays
- 5.4.1. U.S. ATP Assays Market, by Enzymatic ATP Assays, by Region, 2020-2034 (USD Billion)
5.5. Bioluminescence Resonance Energy Transfer (BRET) ATP Assays
- 5.5.1. U.S. ATP Assays Market, by Bioluminescence Resonance Energy Transfer (BRET) ATP Assays, by Region, 2020-2034 (USD Billion)
5.6. Cell-based ATP Assays
- 5.6.1. U.S. ATP Assays Market, by Cell-based ATP Assays, by Region, 2020-2034 (USD Billion)
5.7. Others
- 5.7.1. U.S. ATP Assays Market, by Others, by Region, 2020-2034 (USD Billion)

6. U.S. ATP Assays Market, by Application

6.1. Key Findings
6.2. Introduction
- 6.2.1. U.S. ATP Assays Market, by Application, 2020-2034 (USD Billion)
6.3. Drug Discovery and Development
- 6.3.1. U.S. ATP Assays Market, by Drug Discovery and Development, by Region, 2020-2034 (USD Billion)
6.4. Clinical Diagnostics
- 6.4.1. U.S. ATP Assays Market, by Clinical Diagnostics, by Region, 2020-2034 (USD Billion)
6.5. Environmental Testing
- 6.5.1. U.S. ATP Assays Market, by Environmental Testing, by Region, 2020-2034 (USD Billion)
6.6. Food Safety and Quality Testing
- 6.6.1. U.S. ATP Assays Market, by Food Safety and Quality Testing, by Region, 2020-2034 (USD Billion)
6.7. Others
- 6.7.1. U.S. ATP Assays Market, by Others, by Region, 2020-2034 (USD Billion)

7. U.S. ATP Assays Market, by End Use

7.1. Key Findings
7.2. Introduction
- 7.2.1. U.S. ATP Assays Market, by End Use, 2020-2034 (USD Billion)
7.3. Pharmaceutical and Biotechnology Companies
- 7.3.1. U.S. ATP Assays Market, by Pharmaceutical and Biotechnology Companies, by Region, 2020-2034 (USD Billion)
7.4. Academic and Research Institutes
- 7.4.1. U.S. ATP Assays Market, by Academic and Research Institutes, by Region, 2020-2034 (USD Billion)
7.5. Hospital and Diagnostics Laboratories
- 7.5.1. U.S. ATP Assays Market, by Hospital and Diagnostics Laboratories, by Region, 2020-2034 (USD Billion)

8. Competitive Landscape

8.1. Expansion and Acquisition Analysis
- 8.1.1. Expansion
- 8.1.2. Acquisitions
8.2. Partnerships/Collaborations/Agreements/Exhibitions

9. Company Profiles

9.1. Abcam plc
- 9.1.1. Company Overview
- 9.1.2. Financial Performance
- 9.1.3. Product Benchmarking
- 9.1.4. Recent Development
9.2. Becton, Dickinson and Company (BD)
- 9.2.1. Company Overview
- 9.2.2. Financial Performance
- 9.2.3. Product Benchmarking
- 9.2.4. Recent Development
9.3. Biomerieux SA
- 9.3.1. Company Overview
- 9.3.2. Financial Performance
- 9.3.3. Product Benchmarking
- 9.3.4. Recent Development
9.4. Biotium
- 9.4.1. Company Overview
- 9.4.2. Financial Performance
- 9.4.3. Product Benchmarking
- 9.4.4. Recent Development
9.5. Lonza Group Ltd.
- 9.5.1. Company Overview
- 9.5.2. Financial Performance
- 9.5.3. Product Benchmarking
- 9.5.4. Recent Development
9.6. Merck KGaA
- 9.6.1. Company Overview
- 9.6.2. Financial Performance
- 9.6.3. Product Benchmarking
- 9.6.4. Recent Development
9.7. PerkinElmer Inc.
- 9.7.1. Company Overview
- 9.7.2. Financial Performance
- 9.7.3. Product Benchmarking
- 9.7.4. Recent Development
9.8. Promega Corporation
- 9.8.1. Company Overview
- 9.8.2. Financial Performance
- 9.8.3. Product Benchmarking
- 9.8.4. Recent Development
9.9. Quest Diagnostics Incorporated
- 9.9.1. Company Overview
- 9.9.2. Financial Performance
- 9.9.3. Product Benchmarking
- 9.9.4. Recent Development
9.10. Thermo Fisher Scientific
- 9.10.1. Company Overview
- 9.10.2. Financial Performance
- 9.10.3. Product Benchmarking
- 9.10.4. Recent Development